Fudan University, 150 million transfer of 1.1 new drugs, motherwort

On December 1st, at the Fufu Building of Fudan University, Fudan University and Zhongzhu Medical officially signed the “World Exclusive Transfer Contract for the New Drug Motherwort (SCM-198) Project”. Academician of the Chinese Academy of Sciences, Vice President of Fudan University, Jin Li, Chairman of China Pearl Medical Holdings Co., Ltd. Xu Delai and other relevant personnel attended the signing ceremony and delivered speeches. Academician of the Chinese Academy of Engineering, researcher of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tang Xican, Shanghai Science and Technology Commission Mr. Xu Kaiyu, former deputy director of the State Food and Drug Administration Ren Dequan, and Wang Longxing, chairman of the Shanghai Pharmaceutical Association, and other experts and scholars attended the meeting and witnessed the signing.

It is reported that motherwort is also known as SCM-198 monomer compound. It is the traditional Chinese medicine resource of Fudan University and its team. After more than 10 years of independent research and development, it has been selected from traditional gynecological drug motherwort. The active monomer can be used to develop 1.1 new drugs for cardiovascular and cerebrovascular protection. At present, it has basically completed pre-clinical research and development, and has successively obtained the national “Major New Drug Creation” major scientific and technological projects “Eleventh Five-Year Plan” and “Twelfth Five-Year Plan”. In 2012, it was awarded as one of the original Class I new drugs in the “Triple” project by the Ministry of Science and Technology and the State Administration of Traditional Chinese Medicine .

According to experts in the industry, motherwort has been shown to inhibit atherosclerotic plaque inflammation and reduce the infarct size of cerebral cortex caused by cerebral ischemia. It has obvious curative effect on lipid-lowering and treatment of stroke, and it has a rapid and significant effect on acute stroke treatment. . "If this medicine is successful, it is definitely a heavy one." The relevant person in charge of Zhongzhu Medical introduced.

According to the announcement of Zhongzhu Medical, the transfer covers 8 patents obtained during the research and development of the new drug motherwort (SCM-198) project, technical secrets related to the preparation of motherwort, preclinical research data and production process related materials. The total amount of the transfer contract was 150 million yuan, and the milestone payment method was adopted. Among them, the early technology transfer fee (8 patent transfer) was 18 million yuan, and the follow-up development milestone was 132 million yuan.